CA3197381A1 - Use of isatuximab for the treatment of multiple myeloma - Google Patents

Use of isatuximab for the treatment of multiple myeloma

Info

Publication number
CA3197381A1
CA3197381A1 CA3197381A CA3197381A CA3197381A1 CA 3197381 A1 CA3197381 A1 CA 3197381A1 CA 3197381 A CA3197381 A CA 3197381A CA 3197381 A CA3197381 A CA 3197381A CA 3197381 A1 CA3197381 A1 CA 3197381A1
Authority
CA
Canada
Prior art keywords
individual
month
antibody
serum
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3197381A
Other languages
English (en)
French (fr)
Inventor
Dorothee Semiond
Hoai-Thu THAI
Helgi Van De Velde
Christine VEYRAT-FOLLET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3197381A1 publication Critical patent/CA3197381A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
CA3197381A 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma Pending CA3197381A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063109305P 2020-11-03 2020-11-03
US63/109,305 2020-11-03
US202163239108P 2021-08-31 2021-08-31
US63/239,108 2021-08-31
PCT/US2021/072193 WO2022099257A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
CA3197381A1 true CA3197381A1 (en) 2022-05-12

Family

ID=78825149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3197381A Pending CA3197381A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Country Status (8)

Country Link
US (1) US20220135696A1 (https=)
EP (1) EP4240416A1 (https=)
JP (1) JP2023550311A (https=)
AU (1) AU2021376374A1 (https=)
CA (1) CA3197381A1 (https=)
IL (1) IL302640A (https=)
TW (1) TW202233235A (https=)
WO (1) WO2022099257A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
KR20210006321A (ko) * 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
WO2020212912A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
EP3969004A1 (en) * 2019-05-14 2022-03-23 Sanofi Methods of administering anti-cd38 antibody to treat multiple myeloma

Also Published As

Publication number Publication date
IL302640A (en) 2023-07-01
EP4240416A1 (en) 2023-09-13
WO2022099257A1 (en) 2022-05-12
JP2023550311A (ja) 2023-12-01
TW202233235A (zh) 2022-09-01
US20220135696A1 (en) 2022-05-05
AU2021376374A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Mould et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development
Tabrizi et al. Preclinical and clinical safety of monoclonal antibodies
JP7712206B2 (ja) 多発性骨髄腫の処置方法
EP4559477A2 (en) Compositions and methods for treating cancer
CN109134652A (zh) Pan-ELR+ CXC 趋化因子抗体
CN116322769A (zh) 用于治疗多发性骨髓瘤的方法
US12528868B2 (en) CD1a antibodies and uses thereof
US20220135696A1 (en) Use of isatuximab for the treatment of multiple myeloma
JP2025138745A (ja) 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
US20250177519A1 (en) Use of isatuximab in combination with other agents for the treatment of multiple myeloma
WO2022042681A1 (en) Use of an anti-pd-1 antibody and a cytotoxic anticancer drug in treatment of non-small cell lung cancer
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
CN116761627A (zh) 艾萨妥昔单抗用于治疗多发性骨髓瘤的用途
CA3048198A1 (en) Methods of treating multiple myeloma
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
WO2025109518A1 (en) Methods for treatment of myeloproliferative neoplasms

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241021

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241021

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241021

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250827

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250827

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031